Robert Breedlove
Vermögen: 647 477 $ am 31.08.2026
Vermögen: 647 477 $ am 31.08.2026
Robert Breedlove is Chief Accounting Officer & Vice President-Finance at Phathom Pharmaceuticals, Inc. since 2025.
Former roles include Manager-Financial Reporting & Compliance at NeoGenomics, Inc. and Senior Manager at Van Den Boom & Associates LLC.
Education includes an undergraduate degree from the University of San Diego.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 03.09.2026 | 67.657 ( 0,08 % ) | 647 477 $ | 31.08.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| PHATHOM PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 06.10.2025 |
| Unternehmen | Position | Ende |
|---|---|---|
| NEOGENOMICS, INC. | Compliance Officer | - |
Van Den Boom & Associates LLC
Van Den Boom & Associates LLC Miscellaneous Commercial ServicesCommercial Services Provides accounting, financial, payroll, benefit and human resource services | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 4 |
|---|---|
NeoGenomics, Inc.
NeoGenomics, Inc. Medical/Nursing ServicesHealth Services Provides genetic and molecular testing services | Health Services |
University of San Diego
University of San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Van Den Boom & Associates LLC
Van Den Boom & Associates LLC Miscellaneous Commercial ServicesCommercial Services Provides accounting, financial, payroll, benefit and human resource services | Commercial Services |
Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel treatments for gastrointestinal diseases and disorders | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen